Dreher - Figure 17
Eligibility for NIV
The same panel of experts mentioned in Figure 16 also concluded that current data support the following recommendations:[7] Patients with COPD with a waking PaCO2 >50–52 mmHg, or an overnight PaCO2 >55 mmHg, or both, who are symptomatic and compliant with other therapies, should be eligible for treatment with NIV.
Dreher M. Chest 2017:00.
References
[7]
White DP, Criner GJ, Dreher M, et al. The role of noninvasive ventilation in the management and mitigation of exacerbations and hospital admissions/readmissions for the patient with moderate to severe COPD (multimedia activity). Chest. 2015;147:1704−5. doi: 10.1378/chest.15-0394.